The serum. b) ELISA for IgG antibodies to rNP in the BAL. c) ELISA for IgA antibodies to rNP in the BAL. d) ELISPOT for IFN-c T cell responses. Results for three mice per group are reported as number of IFN-c secreting cells per 106 cells. Black bars, stimulation with NP147?55 peptide. Gray bars, stimulation with SARS209?21 peptide. Top: T cells in the lungs. Bottom: T cells in the spleen. Bars show mean 6 SEM of pooled group triplicates, not individual animals. doi:10.1371/journal.pone.0055435.ginduced modest Dimethylenastron responses to the adenovirus peptide Dbp419?27 (Fig. 5). A hundred-fold lower dose of PanAd3-NPM1 induced little response to either NP147?55 or Dbp419?27. Immune protection against challenge infection. One month after immunization mice were challenged with 100 LD50 (104 TCID50) of A/FM, a relatively high dose of a highly pathogenic virus. As shown in Figure 6, a dose of 107 vp or less did not protect, but at a dose of 109 vp PanAd3-NPM1 provided considerable protection against this stringent challenge. Most mice survived and displayed much less morbidity than controls, as shown by weight loss. Cross-neutralization by human antibodies to Ad5. Ad5 and PanAd3 are closely related viruses, both belonging to adenovirus group C [34]. As one aspect of whether PanAdvectors are likely to be blocked by pre-existing immunity to Ad5, we tested neutralization of a PanAd3 virus by human sera selected for particularly high neutralizing antibody to Ad5 (titers .1000). As shown in Table S1, many of these high-titered sera had no neutralizing activity on PanAd3. Some of the human sera with very high neutralizing titers ranging from 1628 to 4608 on Ad5 had low neutralizing titers of 28?3 on PanAd3.DiscussionIn the efforts to develop a universal influenza vaccine, various platforms for immunization to conserved antigens have been studied. Replication incompetent adenovirus vectors are promising, since their strong induction of innate immune responsesHighly Immunogenic Simian Adenovirus VectorFigure 4. Antibody responses to different doses of PanAd3NPM1. Mice were vaccinated with indicated doses. Four weeks later mice were sacrificed, and serum and BAL were collected for antibody analysis. Error bars indicate mean 6 SEM. a) ELISA for IgG antibodies to rNP in the serum and BAL. b) ELISA for IgA antibodies to rNP in the serum and BAL. c) ELISA for IgG antibodies to rM1 in the serum and BAL. doi:10.1371/journal.pone.0055435.gprovides a built-in adjuvant, and the antigen-specific B and T cell responses they induce are sustained for a long time [21]. Animal adenoviruses have the potential advantage that humans have no prior exposure to them. For that reason chimpanzee adenoviruses have recently begun to be explored for use as vaccine vectors in humans, where they showed good safety and excellent immunogenicity [27,29,46]. Furthermore, in tests of Ad5 and four chimpanzee adenovirus vectors, prior immunization with a GFPexpressing construct blocked subsequent responses to the transgene product only for homologous vector; cross-blocking was MedChemExpress Eliglustat minimal [34].In this study, we tested a new vector based on bonobo virus PanAd3. Both Ad5 and bonobo virus PanAd3 belong to the adenovirus species C [34]. Species B (for example Ad35) has been shown in other studies to be less immunogenic than species C [47]. Since they are so closely related, Ad5 and PanAd3 may share certain structural features providing powerful internal adjuvant effects and thus higher immunogenicity. De.The serum. b) ELISA for IgG antibodies to rNP in the BAL. c) ELISA for IgA antibodies to rNP in the BAL. d) ELISPOT for IFN-c T cell responses. Results for three mice per group are reported as number of IFN-c secreting cells per 106 cells. Black bars, stimulation with NP147?55 peptide. Gray bars, stimulation with SARS209?21 peptide. Top: T cells in the lungs. Bottom: T cells in the spleen. Bars show mean 6 SEM of pooled group triplicates, not individual animals. doi:10.1371/journal.pone.0055435.ginduced modest responses to the adenovirus peptide Dbp419?27 (Fig. 5). A hundred-fold lower dose of PanAd3-NPM1 induced little response to either NP147?55 or Dbp419?27. Immune protection against challenge infection. One month after immunization mice were challenged with 100 LD50 (104 TCID50) of A/FM, a relatively high dose of a highly pathogenic virus. As shown in Figure 6, a dose of 107 vp or less did not protect, but at a dose of 109 vp PanAd3-NPM1 provided considerable protection against this stringent challenge. Most mice survived and displayed much less morbidity than controls, as shown by weight loss. Cross-neutralization by human antibodies to Ad5. Ad5 and PanAd3 are closely related viruses, both belonging to adenovirus group C [34]. As one aspect of whether PanAdvectors are likely to be blocked by pre-existing immunity to Ad5, we tested neutralization of a PanAd3 virus by human sera selected for particularly high neutralizing antibody to Ad5 (titers .1000). As shown in Table S1, many of these high-titered sera had no neutralizing activity on PanAd3. Some of the human sera with very high neutralizing titers ranging from 1628 to 4608 on Ad5 had low neutralizing titers of 28?3 on PanAd3.DiscussionIn the efforts to develop a universal influenza vaccine, various platforms for immunization to conserved antigens have been studied. Replication incompetent adenovirus vectors are promising, since their strong induction of innate immune responsesHighly Immunogenic Simian Adenovirus VectorFigure 4. Antibody responses to different doses of PanAd3NPM1. Mice were vaccinated with indicated doses. Four weeks later mice were sacrificed, and serum and BAL were collected for antibody analysis. Error bars indicate mean 6 SEM. a) ELISA for IgG antibodies to rNP in the serum and BAL. b) ELISA for IgA antibodies to rNP in the serum and BAL. c) ELISA for IgG antibodies to rM1 in the serum and BAL. doi:10.1371/journal.pone.0055435.gprovides a built-in adjuvant, and the antigen-specific B and T cell responses they induce are sustained for a long time [21]. Animal adenoviruses have the potential advantage that humans have no prior exposure to them. For that reason chimpanzee adenoviruses have recently begun to be explored for use as vaccine vectors in humans, where they showed good safety and excellent immunogenicity [27,29,46]. Furthermore, in tests of Ad5 and four chimpanzee adenovirus vectors, prior immunization with a GFPexpressing construct blocked subsequent responses to the transgene product only for homologous vector; cross-blocking was minimal [34].In this study, we tested a new vector based on bonobo virus PanAd3. Both Ad5 and bonobo virus PanAd3 belong to the adenovirus species C [34]. Species B (for example Ad35) has been shown in other studies to be less immunogenic than species C [47]. Since they are so closely related, Ad5 and PanAd3 may share certain structural features providing powerful internal adjuvant effects and thus higher immunogenicity. De.
